Advanced nanodelivery platforms for topical ophthalmic drug delivery.

2021 
Conventional eye drops have several limitations, including the need for multiple applications per dose, hourly based dosage regiments, and suboptimal ocular bioavailability (<5%). The efficacy of topical ophthalmic medications can be significantly improved by controlling their contact time with the adherent mucin layer and by inducing sustained release properties, thus allowing for a prolonged contact time of the drug with ocular tissues, which eventually will lead to improved drug bioavailability and a significant decrease in the frequency of eyedrop instillation. In this review, we critically highlight recent and innovative nanodrug delivery platforms, with a primary focus on the integration of nanotechnology, biomaterials, and chemistry to facilitate precise spatial and temporal control over sustained drug release to the cornea.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    86
    References
    4
    Citations
    NaN
    KQI
    []